Table 1 Baseline characteristics and prior treatment
From: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Characteristics | Total (n = 123) |
|---|---|
Median age (range), years | 68.0 (36–89) |
Male, n (%) | 68 (55.3) |
Race, n (%) | |
White | 72 (58.5) |
Asian | 16 (13.0) |
Black or African American | 9 (7.3) |
Not reported or unknowna | 26 (21.1) |
Geographical region, n (%) | |
North America | 58 (47.2) |
Europe | 45 (36.6) |
Asia | 12 (9.8) |
Other | 8 (6.5) |
ECOG performance status, n (%) | |
0 | 45 (36.6) |
1 | 71 (57.7) |
2 | 7 (5.7) |
Type of myeloma, n (%) | |
IgG | 65 (52.8) |
Non-IgG | 21 (17.1) |
IgA | 20 (16.3) |
IgD | 1 (0.8) |
Light chain | 24 (19.5) |
Unknown | 13 (10.6) |
R-ISS disease stage, n (%) | |
I | 28 (22.8) |
II | 68 (55.3) |
III | 19 (15.4) |
Unknown | 8 (6.5) |
Cytogenetic risk, n (%) | |
Standard | 83 (67.5) |
Highb | 31 (25.2) |
Missing | 9 (7.3) |
Extramedullary disease by BICR, n (%)c | 39 (31.7) |
Bone marrow plasma cells, n (%) | |
<50% | 89 (72.4) |
≥50% | 26 (21.1) |
Missing | 8 (6.5) |
≥1 poor prognosis featured | 94 (76.4) |
Median no. of prior antimyeloma lines of therapy (range) | 5 (2–22) |
Prior stem cell transplant, n (%) | 87 (70.7) |
Exposure status, n (%) | |
Triple-classe | 123 (100) |
Penta-drugf | 87 (70.7) |
Refractory status, n (%) | |
Triple-classe | 119 (96.7) |
Penta-drugf | 52 (42.3) |
Refractory to last line of therapy, n (%) | 118 (95.9) |
